Finally, there is some variability in survival outcomes in patients with MUM, which may be explained by differences in molecular and cytogenetic mutations of the tumor; monosomy 3 tumors appear to have worse outcomes and SF3B1 mutated tumors with improved outcomes, but this needs to be elucidated further [16,158,202]. Here, SF3B1 is linked to neoplasm.